



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS TO HOST R&D DAY

Taipei, Taiwan, 28 November 2017 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, will host its first R&D day in Taipei, Taiwan, on 29 November 2017.

Members of ASLAN's senior management, with key opinion leaders and industry experts, will provide an overview of ASLAN's pipeline of novel drugs, along with updates on their progress and clinical status. Speakers include:

- Dr Cheng-Hsu Wang, Chairman, HOPE Foundation for Cancer Care
- Dr Matthew Ng, Senior Consultant, National Cancer Centre Singapore
- Dr Chin Hin Ng, Consultant, National University Cancer Institute Singapore
- Dr Carl Firth, Chairman & CEO, ASLAN Pharmaceuticals
- Dr Mark McHale, Chief Operating Officer, ASLAN Pharmaceuticals
- Dr Bertil Lindmark, Chief Medical Officer, ASLAN Pharmaceuticals
- Dr Chih-Yih Hsieh, Vice President (Medical) and General Manager (Taiwan), ASLAN Pharmaceuticals

No new company information will be shared at this event.

The event is open to analysts, institutional investors and members of the media. For more information, please email [Wendy.Kao@aslanpharma.com](mailto:Wendy.Kao@aslanpharma.com).

ENDS

#### Media contacts

##### Chris Fang

ASLAN Pharmaceuticals

Tel: +886 2 2758 3333

E-mail: [media@aslanpharma.com](mailto:media@aslanpharma.com)

##### Emma Thompson / Stephanie Tan

Spurwing Communications

Tel: +65 6340 7287

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

#### About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (6497.TT) is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and colorectal cancer, with the lead programme in pivotal studies. ASLAN's partners include Array BioPharma, Bristol-Myers Squibb, Ammirall and CSL.

[www.aslanpharma.com](http://www.aslanpharma.com)

#### Cautionary statement

*All materials and information set out herein are for reference only and whilst we make every effort to ensure accuracy and completeness, we cannot guarantee this. We make no recommendation as to the competence or suitability of persons or entities referenced herein (if any). Nothing herein constitutes an invitation or offer to invest in or deal in the securities of ASLAN. Anyone considering investment in ASLAN should refer to the information officially published the Taiwan Stock Exchange Market Observation System (MOPS). All forward-looking statements*



*attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on such forward-looking statements, which are inherently unreliable, and you should not rely on them. Any such forward-looking statement will have been based on ASLAN's expectations, assumptions, estimates and projections about future events on the date(s) made. Actual outcomes are subject to numerous risks and uncertainties, many of which relate to factors beyond ASLAN's control, that could cause them to differ materially from those expressed in a forward-looking statement. ASLAN has no obligation to update or otherwise revise any forward-looking statements to reflect the occurrence of unanticipated events or for any other reason.*